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Edited by Sandro SonninoAbstract Apolipoprotein M (apoM) is predominantly associ-
ated with HDL. In this study, it was investigated whether
apoMs uncleaved signal peptide is necessary for the proteins
ability to associate with lipoproteins. ApoM with a cleavable
signal peptide, Q22A, was expressed, together with wild-type
apoM, in HEK293 cells. On size-exclusion chromatography,
the elution proﬁle of wild-type apoM was similar to that of
human HDL-associated plasma apoM. In contrast, the size of
the Q22A mutant corresponded to free, unassociated apoM. This
strongly indicates that the signal peptide is indeed necessary for
apoMs ability to associate with lipid.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apolipoprotein M (apoM) is composed of 188 amino acids
and has an apparent molecular weight of 25 kDa [1]. Struc-
tural analysis and homology modelling have predicted that
apoM belongs to the lipocalin protein superfamily, and a
three-dimensional model has been constructed [2]. Although
the protein is found in all major lipoprotein classes, the major-
ity of apoM is found in high density lipoprotein, HDL [1]. In
human plasma, the apoM concentration is approximately
0.9 lmol/l [3].
In healthy humans, the level of ApoM is mainly correlated
to plasma total cholesterol (r = 0.52) [3]. The mechanism be-
hind this relationship is not known. ApoM has been shown
to be a target gene for the orphan nuclear receptor liver recep-
tor homolog-1 (LRH-1) [4], a regulator of genes that decrease
cholesterol levels in liver and intestine [5], and HNF-1a, muta-
tions in which gene are responsible for maturity onset of dia-
betes in the young type 3 (MODY3) [6].
The biological role of the protein is not fully understood.
Two studies have demonstrated that overexpression of apoM
reduces the development of atherosclerosis in LDLr/ mice
challenged with a cholesterol-rich diet [7,8]. However, a recent
report, based on more than 2000 samples from two separate
Nordic prospective case–control studies, found no association
between plasma apoM concentration and the risk of a coro-*Corresponding author. Fax: +46 40 337044.
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doi:10.1016/j.febslet.2008.02.007nary heart disease event (Ahnstro¨m, Axler and Dahlba¨ck,
manuscript in preparation).
A most unusual feature of apoM is that the signal peptide
remains uncleaved in the circulating protein [1]. Normally,
the signal peptide mediates import into the endoplasmic retic-
ulum and is then cleaved by a type I signal peptidase after
translocation [9]. To our knowledge, an uncleaved signal pep-
tide has only been described for two other exported proteins,
paraoxonase 1 (PON-1) and haptoglobin-related protein
(HPR) [10]. For PON-1, the signal peptide has been described
to be necessary for lipoprotein association [11].
In this study, it was investigated whether the hydrophobic
signal peptide is similarly responsible for apoMs ability to
associate with lipoproteins and if a signal peptidase cleavage
site could be generated with a single Q22A point mutation.2. Materials and methods
2.1. Transfection and expression of WT and Q22A apoM in HEK293
cells
The ampliﬁcation and cloning into the pcDNA3 vector (Invitrogen)
of wild-type (WT) apoM has been described previously [1]. The Q22A
mutation was introduced into pcDNA3 containing WT apoM by site-
directed mutagenesis employing a QuikChange kit (Stratagene),
according to the manufacturers instructions. DNA sequencing was
performed using a PE Applied Biosystems sequencing kit. Stable trans-
fection of HEK293 cells was performed using Lipofectin (Invitrogen)
according to a procedure described earlier [12] and colonies were
screened for apoM expression by Western blotting. For all experi-
ments, WT and Q22A apoM-transfected cells, as well as cells transfec-
ted with empty pcDNA3 vector, were grown in 75 cm2 TC Easy Flasks
(Nunc), containing 25 ml Dulbeccos modiﬁed medium with 10% fetal
calf serum, until 90% conﬂuent. Thereafter, fresh medium was ap-
plied and cells were incubated for another 48 h, after which medium
was collected and stored at 4 C.2.2. ApoM sandwich ELISA
A sandwich ELISA for apoM based on two monoclonal antibodies
was used to quantify apoM as previously described [3]. The Q22A mu-
tant was quantiﬁed against a standard curve prepared from recombi-
nantly expressed signal peptide-free apoM.2.3. Western blotting
Western blotting analysis of plasma and cell medium from HEK293
cells was performed according to a procedure described previously [13]
using polyclonal anti-human apoM antiserum [14] that had been aﬃn-
ity-puriﬁed on two 5 ml protein A and G-coupled HiTrap columns
(GE Healthcare) according to the manufacturers instructions.2.4. ApoM particle size determination
Gel ﬁltration was performed on an A¨KTA fast performance liquid
chromatography (FPLC) system (Amersham Pharmacia Biotech) toblished by Elsevier B.V. All rights reserved.
Fig. 1. Results from Western blotting of plasma (P) and medium from
HEK293 cells transfected with pcDNA3 vector containing WT or
Q22A apoM or empty vector (B). 0.5 ll of plasma and 10 ll of cell
medium were loaded onto a 12% SDS–PAGE gel, transferred to a
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Amersham Pharmacia Biotech) equilibrated with 20 mM Tris pH 7.5
containing 150 mM NaCl, 0.1% bovine serum albumin and 5 mM
EDTA. Flow rate was 0.6 ml/min. The elution volume (Ve) was mon-
itored by absorbance at 280 nm. The partition coeﬃcient, Kav, was cal-
culated from the elution volume, Ve, and total bed volume, Vt, using
the equation Kav = (Ve  V0)/(Vt  V0), where V0 is the exclusion vol-
ume as determined by the elution volume of dextran blue. The total
bed volume was determined by the exclusion volume and the elution
volume of acetone. The Stokes radius (RST) of apoM-containing par-
ticles was calculated from a linear calibration plot of RST versus
(logKav)1/2 obtained with thyroglobulin A (RST 85 A˚), ferritin
(RST 61 A˚), aldolase (RST 48.1 A˚), ovalbumin (RST 30.5 A˚), and bo-
vine pancreatic ribonuclease A (RST 16.4 A˚, all Amersham Pharmacia
Biotech).PVDF membrane and blotted with rabbit polyclonal anti-human
apoM antiserum. The markers represent apparent molecular weight in
kilodaltons derived from a molecular weight standard run in an
adjacent lane.3. Results and discussion
In order to examine whether the retained signal peptide of
apoM is necessary for the proteins ability to associate with
lipoproteins, apoM with a cleavable signal peptide, expressed
in a eukaryotic cell system, was considered the preferred mod-
el. A central feature of signal peptides cleavable by a type I sig-
nal peptidase is that the central hydrophobic region is followed
by small and neutral residues at positions 3 and 1 relative
to the cleavage site [15]. The amino acid sequence for human
apoM was analysed by SignalP 3.0, a neural networks-based
signal peptide prediction tool [16,17], which identiﬁed a likely
cleavage site between positions 22 and 23. Substituting the
comparatively bulky glutamine in position 22 (i.e. 1 relative
to the cleavage site) for the residue most common at this posi-
tion, alanine, predictably increased the maximum c-score
(‘‘cleavage site score’’) from 0.17 to 0.64. This is well above
the cut-oﬀ value of 0.32, indicating a high probability that this
construct would be cleaved in eukaryotic cells.
This mutation, Q22A, was introduced into a pcDNA3 vector
containing WT apoM by site-directed mutagenesis and con-
ﬁrmed by DNA sequencing. The WT and Q22A apoM con-
structs, as well as empty pcDNA3 vector, were introduced
into HEK293 cells by transfection. ApoM levels in medium
from both WT and Q22A transfected cells were approximately
0.5 mg/l in medium collected after 48 h as determined by ELI-
SA. No apoM signal was detected in medium from cells trans-Fig. 2. Results from size-exclusion chromatography. Human pooled plasma
(open boxes) and Q22A apoM (open triangles) was run on a Superose 12 colu
The minor peak at elution volume 8.5 ml observed for human plasma reprefected with empty vector. In an earlier study, Q22A apoM
displayed similar immunoreactivity in a monoclonal anti-
body-based ELISA to plasma-derived apoM and a similar par-
tial glycosylation pattern, indicating that it was correctly
folded [12]. Successful cleavage of the signal peptide was veri-
ﬁed by Western blotting (Fig. 1). It was additionally conﬁrmed
by Western blotting using polyclonal rabbit antiserum against
the signal peptide of apoM. No signal peptide could be de-
tected for Q22A (picture not shown).
To investigate whether signal peptide-free apoM retained the
ability to associate with apolipoproteins, WT and Q22A apoM
cell medium, together with pooled human plasma, was sub-
jected to size-exclusion chromatography employing a cali-
brated Superose 12 column (Fig. 2). Fractions were analysed
by ELISA. The elution proﬁle achieved from WT apoM med-
ium corresponded well to that of pooled human plasma, with
peak fractions giving a calculated Stokes radius of, respec-
tively, 62.9 and 64.5 A˚. This corresponds to the size of apoM-
containing HDL [14], indicating that WT apoM mainly associ-
ated with bovine HDL. In contrast, apoM in Q22A medium
eluted considerably later, with a calculated Stokes radius in
the peak fraction of 31.8 A˚, a size corresponding to free, unas-
sociated apoM. Compared to the narrow peak achieved for
Q22A medium, the peak achieved for plasma and WT apoM(black circles) and medium from HEK293 cells expressing WT apoM
mn. The fraction size was 0.25 ml and apoM was quantiﬁed by ELISA.
sents apoM in apoB-containing lipoproteins.
828 O. Axler et al. / FEBS Letters 582 (2008) 826–828was broader. This is in line with earlier observations [14] and
reﬂects the heterogeneity of apoM-containing HDL particles.
In conclusion, apoM with a cleavable signal peptide was
constructed and expressed in HEK293 cells. In contrast to
wild-type apoM which associated to HDL as predicted, signal
peptide-free apoM did not associate with lipoproteins, strongly
indicating that the signal peptide is necessary for apoMs abil-
ity to associate with lipid.
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